Swiss cost-effectiveness analysis of universal screening for Lynch syndrome of patients with colorectal cancer followed by cascade genetic testing of relatives. Issue 9 (15th November 2021)

• Record Type: Journal Article
• Authors: Salikhanov, Islam; Heinimann, Karl; Chappuis, Pierre; Buerki, Nicole; Graffeo, Rossella; Heinzelmann, Viola; Rabaglio, Manuela; Taborelli, Monica; Wieser, Simon; Katapodi, Maria C.
• Is Part Of: Journal of medical genetics. Volume 59:Issue 9(2022)
• Page Start: 924
• Page End: 930
• Publication Date: 2021-11-15
• Subjects: costs and cost analysis -- gastrointestinal diseases -- genetic counseling -- health care economics and organizations -- genetic testing; Medical genetics -- Periodicals; 616.042
• DOI: 10.1136/jmedgenet-2021-108062
• Languages: English
• ISSNs: 1468-6244

Abstract

Abstract : Background: We estimated the cost-effectiveness of universal DNA screening for Lynch syndrome (LS) among newly diagnosed patients with colorectal cancer (CRC) followed by cascade screening of relatives from the Swiss healthcare system perspective. Methods: We integrated decision trees with Markov models to calculate incremental cost per quality-adjusted life-year saved by screening all patients with CRC (alternative strategy) compared with CRC tumour-based testing followed by DNA sequencing (current strategy). Results: The alternative strategy has an incremental cost-effectiveness ratio of CHF65 058 compared with the current strategy, which is cost-effective according to Swiss standards. Based on annual incidence of CRC in Switzerland, universal DNA screening correctly identifies all 123 patients with CRC with LS, prevents 17 LS deaths and avoids 19 CRC cases, while the current strategy leads to 32 false negative results and 253 LS cases lost to follow-up. One way and probabilistic sensitivity analyses showed that universal DNA testing is cost-effective in around 80% of scenarios, and that the cost of DNA testing and the number of invited relatives per LS case determine the cost-effectiveness ratio. Conclusion: Results can inform policymakers, healthcare providers and insurance companies about the costs and benefits associated with universal screening for LS and cascade genetic testing of relatives.